




PHARMACEUTICAL 2022

LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 307 of 466





PHARMACEUTICAL 2022

LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 307 of 466

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 22% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	5,093
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	303
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,060
Other Liabilities	0
Other Net Income	-0.54
Other Revenues	0
Property and Equipment	0
Research and Development	1,737
Selling, General and Administrative Expense	2,931

Output Variable	Value in 1000 USD
Assets	5,093
Liabilities	303
Expenses	6,728
Revenues	0
Stockholders Equity	4,790
Net Income	-6,728
Comprehensive Net Income	-6,728
Economic Capital Ratio	56%